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Summary.-Primary human squamous-cell lung tumours were disrupted using
mechanical high-speed homogenization. Crude membranes were isolated by dif-
ferential centrifugation at low speeds followed by 100,000 g centrifugation. Such
membrane preparations were extracted with Triton-X-100 and passed over a DEAE
cellulose column; the DEAE unbound fraction and the bound fraction eluted with
0-4M NaCl were used to immunize rabbits. We present here only data on a single
lung-tumour-associated membrane antigen (TAMA) found in the unbound DEAE
cellulose column eluates. This new Triton-X-100 extractable antigen is termed lung
TAMA-1.
A further purification of the antigen was achieved using two methods. The first
used G-200 molecular-seive chromatography and this revealed lung TAMA-1 to
have a mol. wt of200,000. A second method used sucrose density-gradient isoelectric
focusing, and the antigen had an isoelectric point of -3 0.
Several important properties of the lung TAMA-1 were determined. The antigen
has a cathodal gamma-type electrophoretic mobility at pH 7-6. The antigen was not
detected in any normal human adult or foetal tissue extracts tested. It did not cross-
react immunochemically with CEA, AFP or p2 microglobulin. Lung TAMA-1 was
detected in 80% of lung tumour Triton-X-100 extracts tested by counterimmuno-
electrophoresis (CIEP) but was undetectable in breast or colon carcinoma extracts.
Low frequency sonication did not deleteriously affect lung TAMA-1, but, 3M KCI
eliminated its immunologic reactivity in CIEP. Finally, preliminary data were
obtained using immunohistochemistry to localize in vivo lung TAMA-1 production.
THE ISOLATION, identification and puri-
fication of human lung TAA from various
types of lung carcinoma has attracted the
attention of numerous investigators. Such
lung TAA in extracts of primary human
tumours can be demonstrated in the
soluble fraction, in which case they are
present in large quantities and are easily
isolated (Frost et al., 1975; Louis et al.,
1973; Roth et al., 1975; Schlipkoter et al.,
1973; Watson, Smith & Levy, 1974, 1975;
Veltri et al., 1 977; Yachi et al., 1968).
Recently, Braatz et al. (1978) isolated a
saline-extractable lung TAA, present in
only minute concentrations from adeno-
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carcinoma of the lung. The antigen was
detectable only in lung tumour extracts.
Alternatively, lung TAA may be mem-
brane associated and present in lower con-
centrations making them more difficult to
isolate than the soluble lung TAA.
Hollinshead et al. (1974, 1975) extracted
a membrane-bound antigen by low-
frequency sonication, and partially puri-
fied the substance by column chromato-
graphy and polyacrylamide-gel electro-
phoresis. The demonstration of lung TAA
in the circulation of lung-cancer patients
seems to be confined to the soluble type of
lung TAA (Viza et al., 1975; DeCarvalho,R. W. VELTRI, P. E. MAXIM AND J. M. BOEHLECKE
1973; Maxim et al., 1976). Finally, the
demonstration of a cell-mediated immune
response to human lung TAA has in-
volved the use of membrane-extractable
antigens and has used in vivo skin testing
(Hollinshead et al., 1974) and in vitro
methods (Cannon et al., 1977; McCoy et al.,
1977; Dean et al., 1978; Pierce & DeVald,
1975; Roth et al., 1975).
This report establishes the isolation,
identification, purification, and partial
characterization ofa membrane-associated
lung tumour associated membrane antigen
(TAMA). The antigen is referred to as
lung TAMA-1, is extracted with Triton-X-
100, is not identifiable as CEA, AFP, P-2
microglobulin or our lung TAA 1, 2 and 3
(Veltri et al., 1977). We also report
immunohistochemical localization of the
new antigen in vivo.
MATERIALS AND METHODS
Tissueprocurement. Tissues were obtained
at surgery or autopsy through the co-opera-
tion of the Departments of Surgery and
Pathology, West Virginia University Medical
Center (WVU). In addition, Dr Jack Dean
of Litton Bionetics (Bethesda, MD) provided
3 normal lungs, as well as breast and colon
tumour tissues. Tissues obtained from outside
sources were fresh frozen at surgery or
autopsy, shipped under dry ice and stored
frozen until used. Tissues obtained at WVU
were processed immediately after pathological
examination.
Tissue extraction.-Tumour and normal
tissues were minced in balanced salt solution
without glucose and with phenol red, pH
6-6 (BSS). These tissue slices were then
homogenized with a Brinkman Polytron
homogenizer (Model PT1O-35, Brinkman
Instruments, Westbury, N.Y.) using the
PT 10-ST generator. Two 30-sec homogeniza-
tion cycles were used for disruption of the
tissues. Thefirst cycle was atarheostat setting
of 5 (blade speed, 21,000 revs/min) and
produced a cell suspension with connective-
tissue debris. The homogenate was centri-
fuged at 8,000 g for 15 min. The sediment
was resuspended to a 20% w/v suspension
in 0-05M Tris-0-2M EDTA (pH 7.2) buffer.
This was homogenized again at setting
number 8 (blade speed, 55,000 rev/min). The
homogenate was centrifuged at 8,000 g for
15 minutes and the supernatant fluid centri-
fuged again at 100,000 g for 60 min at 40
in a model LS-65 Beckman ultracentrifuge.
The particulate sediment obtained was
termed the crude membrane fraction, and
used for further extractions.
Membrane extraction protocols.-The Triton
X-100 protocol was a modification of the
procedure of Razin (1972). The membrane
fraction was resuspended in 0-05M Tris-0-M
NaCl buffer (pH 7 4) by glass Dounce homo-
genization at a ratio of 100 ml buffer to 01 g
of membrane. Sixteen mg of Triton X-100
(Sigma Chemical Co., St. Louis, MO) per ml
of membrane suspension were added and
stirred at 370 for 30 min. The suspension was
centrifuged at 100,000 g for 60 min at 4°C
and the supernatant fluid dialysed against
PBS for 4-6 days with numerous buffer
changes. The extract was then concentrated
using single hollow fibres (SHF-36, Biomed
Instruments, Chicago, IL).
Membrane fractions were also treated by
3M KCI extraction according to the method
of Meltzer et al. (1971) and by sequential
sonic disruption as per Hollinshead et al.
(1974) and Davies (1966). The exact pro-
cedures used were reported in detail earlier by
Veltri et al. (1977).
DEAE-cellulose chromatography.-Triton
X-100 extracts were equilibrated by dialysis
against 0-05M Tris, 0-04M NaCl (pH 8 0).
They were then applied to a 1-5x25cm
column of DEAE-cellulose equilibrated with
the same buffer. The column was run with
the starting buffer until unbound protein and
Triton X-100 eluted. The bound protein was
then eluted by increasing the NaCl concentra-
tion to 0-4M. Both DEAE fractions were then
concentrated using single hollow fibres.
Immunizationprotocol.-NewZealandwhite
rabbits were obtained locally and were used
to produce antisera to the DEAE-bound
(DEAE 1) and unbound (DEAE 2) Triton
X-100 extracts of human lung tumours. The
details of immunization protocol have been
published elsewhere (Veltri et al., 1977). The
most reactive antiserum to such extracts was
used throughout this study.
Before use in immunoassays the DEAE-1
antiserum was precipitated with ammonium
sulphate at 35% saturation and redissolved
in one half the original volume of distilled
water. The latter was dialysed against 001M
phosphate-buffered saline (PBS) for 48 h at
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4°C. After dialysis the antiserum was adsorbed
with copolymerized normal human serum
(Avrameas and Ternynck, 1969) at a 1:10
ratio of homogenized polymer to antiserum
for 1 h at 370 and overnight at 4°C. This was
followed by solid-phase immunoadsorption
using normal human lung 100,000 g soluble
(5.0 mg protein/ml) adsorbed on to Ultragel
AcA-34 by the method of Guesdon & Avra-
meas (1976). A batch method using 10 ml of
the immunoadsorbent to 1 ml of antiserum
was adsorbed as above. Such adsorption
removed all immunodiffusion reactivity to
normal human serum and soluble proteins of
lung extracts, but a small reactivity to Triton
X-100-extracted normal lung membranes
remained. The latter reactivity was removed
by fluid-phase adsorption of equal volumes
of antiserum and normal lung membrane
Triton extracts (0-5 mg protein/ml).
Immunodiffusion.-Following theextensive
adsorption protocol described above the
antiserum to DEAE-1 of the lung-tumour
Triton X-100 extract was analysed by
Ouchterlony double diffusion (Veltri et al.,
1977).
The agarose-adsorption method of De-
Carvalho (1973) was used for the adsorption
analyses of adsorbed DEAE-1 antiserum.
In addition to the normal Triton extracts,
antiserum wells were also filled with Cohn
fractions (Cohn et al., 1964) ofnormal human
serum (Pentex Labs, Kankakee, IL) normal
saliva or pools of soluble extracts from other
normal organs. The adsorbed antiserum was
then added and diffused against DEAE-
column fractions and controls to determine
whether any of the adsorbents removed
reactivity to the lung tumour antigens.
Identity analysis was performed by Ouch-
terlony double immuno-diffusion using anti-
sera specific to known tumour markers.
Antisera to CEA, AFP and 3-2-microglobulin
were supplied by Drs Charles Todd and
Marianne Egan, Dr Robert McIntire and Dr
Ralph Reisfeld respectively. These and our
antiserum were cross-tested against lung-
tumour Triton X-100 extracts to rule out
cross reactivity. Antisera to serum proteins
known to be elevated during cancer were
obtained from Behring Diagnostics (Sommer-
ville, N.J.) and were tested as above.
Counterimmunoelectrophoresis (CIEP).-
Glass plates 8-2 cm x 10 cm were coated with
20 ml of a solution of 1% Noble agar (Difco,
Detroit, MI) in 0-032M barbital-acetate
buffer, pH 8 6 (Ashcavi, 1973). Paired wells
4 mm in diameter were cut in the agar at an
edge-to-edge distanceof5 mm forlungTAMA
1 determinations.
For the lung TAMA-1 determinations the
antiserum was carbamylated according to
the method ofWeeke (1968) and added to the
cathodal well of each pair. Antigens and
control extracts were added to the anodal
wells. The plates were electrophoresed for
90 min at 125 V, 20 mA at 4°C.
G-200 Sephadex chromatography.-The
medium grade ofSephadex G-200 (Pharmacia
Fine Chemicals, Piscataway, N.J.) was pre-
pared according to manufacturers' instruc-
tions. The running buffer was OO1M K-
phosphate (pH 7 0) containing 0.10% Na azide
and 0.10% Triton X-100. The column was
1-6 x 100cm and it was prepared and run at
room temperature at a flow rate of about
20 ml/h. In order to properly calibrate
the column we used a series of commercially
prepared markers (Pharmacia FineChemicals)
including Blue dextran (2x 106 mol.-wt)
ferritin (440,000) adolase (158,000) oval-
bumin (43,000) ribonuclease-A (13,700) and
catalase (232,000). The lung TAMA-1 was
detected in column fractions after concentra-
tion by immunodiffusion with our adsorbed
DEAE-I antiserum.
Isoelectric focusing (IEF).-The model 212
(ISCO, Lincoln, NB) 1 x 23 cm jacketed
isoelectric focusing column coupled to a Model
UA-5 adsorbance monitor Model 493 electro-
phoresis power supply, and Model 432 pro-
grammed electrophoresis pump were used for
additional purification of lung TAMA-1.
Linear 5-400o sucrose gradients containing
0.10% Triton X-100 and 2% Bio-Lyte
ampholytes, pH 3-10 (BioRad Labs, Rich-
mond, CA) were prepared with an ISCO Model
570 gradient marker. A 5000 sucrose cushion
was placed in the bottom of the IEF column
beforeapplication ofthegradientandsamples.
The ampholyte and samples werethen applied
to the 500o sucrose cushion with a peristaltic
pump interfaced with a 3-way valve (Phar-
macia, Piscataway, N.J.). The samples in
25% sucrose were applied at midpoint of the
gradient, about 13 ml. The upper anodic
chamber contained 1-00% phosphoric acid and
the lower cathodic chamber was filled with
1-0% sodium hydroxide in 40%o sucrose. The
column was maintained at 4°C throughout
our experiments.
All runs were made at a constant wattage
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of 0-42 W and the voltage never exceeded
1100 V during the average run of43 h. Period-
ically the column was monitored at 280 nm
using a programmed electrophoresis pump and
a lem path flow-through cell to assess separa-
tion progress. At the end of the run the
column contents were pumped through the
flow-through cell for a final 280nm scan and
collected in lml volumes and the pH of each
fraction was determined. Regions showing
high absorbance were pooled and the pH
again determined. The pooled regions were
dialysed overnight against 0-O1M PBS (pH
7.2) to remove sucrose and ampholytes. Each
pooled region was then tested for lung TAMA
reactivity by immunodiffusion with the rabbit
antisera to DEAE-1.
Immunoelectrophoresis (JEP).-Immuno-
electrophoretic analysis of lung TAMA-1
used 0.85% Ion Agar (Oxoid, London)
prepared in sodium barbital buffer, ionic
strength=0 05 and pH=7 6. The electro-
phoresis step was made using 38 V and 5 mA
per 1 x 3in microscope slide at 4°C for 3 h.
Subsequently, rabbit anti-lung TAMA-1 was
added to the trough after electrophoresis,
and the slides were incubated overnight at
room temperature in a humidified chamber.
After this ID step, the slides were washed in
0-3M NaCl for 48 h with several changes, air
dried at room temperature, stained in 0 2%
amido black, anddestained in 5:1:1 methanol:
distilled water-acetic acid.
Immunoperoxidase technique.-Formalin-
fixed embeddedsectionsofahumansquamous-
cell carcinoma ofthe lung as well as formalin-
fixed normal human bronchus were used to
test for binding of anti-lung TAMA-1 in situ.
The method is that described by Grandlund
& Andrese (1977).
RESULTS
Identifi cation and purfication of lung
TAMA
Identification of lung TAMA was made
using rabbit antiserum to unbound DEAE
Fraction I prepared from a Triton X-100
extract of a squamous cell carcinoma of
a 65-year-old white male. The antiserum
was adsorbed with pools of normal human
serum, normal human lung soluble extract
and Triton X-100 extracts of normal lung
tissues. The antiserum was then shown to
give a single precipitin band when reacted
FIG. 1. Identification of lung TAAIA-1. The,
adsorbed rabbit antiseruLm to a DEAE I
eltiate of a lung-tumour Triton membrane
extract (TTAIE) (1, centre well) was
testecl against TTMIE (2, a DEAE-1 eluate
of this extract) as well as normal-lung
Triton membrane extract (NLTAIE) (3,pool)
normal sertum pool (NSP) (4), normal lung
soluble pool (NSLP) (5), and T)EAE II
of TTMTE (6). A single precipitin liine shows
immunological identity betwveen lung
TAMA-1 in TT1\IE (1) and its DEAE I (2)
eluate, whereas all controls are non-reactive.
against a human lung-tumour Triton
membrane extract and a DEAE I eluate
of the same (Fig. 1). This antigen was
termed Lung TAMA-1.
Further purification of lung TAMA-1
was as follows. Starting with a squamous-
cell carcinoma Triton X-100 membrane
extract containing 8 05 mg protein we
obtained 2-24 mg of protein in the DEAE
I unbound fraction which had lung
TAMA-1 reactivity by ID (Fig. 1). The
remaining protein which eluted off the
column at a higher salt concentration was
devoid of any such reactivity. Hence,
72% of the total protein had been
eliminated by this first purification.
One mg of the protein from the above
DEAE I region was brought to 25%o
sucrose and added to the IEF column
described above. The final 28nm scan is
shown in Fig. 2; these were collected in
20 x lml fractions which were pooled into
6 regions designated Ri1-R6. The lung
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FIG. 2 FIG. 2(a)
Fia. 2 and 2a. Putrification of lung TAMIA-1 by isoelectric foctusing (IEF). One mg of a TTAIE,
DEAE I eluate was electrofocused in a 5-40% linear sucrose gradient containing a 3-lOpH
ampholyte gra(lient for 43 h at a constant, wattage of 0-42 WV. The elution profile is illustrate(d in
Fig. 2 where the abscissa indicates the pH an(l absorption at 280 mn while tile ordinate indicates
the fractions. The 280nm absorption profile (-) lhas superimposed upon it the pH of each fractioni
(@0). ID+ indicates the poole(d region (R-1) which contains lung TAAIA-1. Fig. 2a illustrates
that only R-1 from the TEF column contains the lung TAMA-1 found in thle DEAE I starting
material (C).
TAMA-1 reactivity was demonstrated by
ID only in R-1 (Fig. 2a) which had a pro-
tein value of 100 [kg or 10% ofthe loading
protein concentration. The pH of R-1 was
3 0.
An additional mode of purification of
lung TAMA-1 used Sephadex G-200
chromatography. We loaded 3 ml con-
taining 600 p.g protein of a DEAE I lung-
tumour membrane Triton extract on to
the 1 6 x 100cm column described above.
The lung TAMA-1 and the calibration
markers were run through this column x 3
to obtain the results shown in Fig. 3. Our
antigen always eluted with about 45% of
the loaded protein at a Kav of 0-25 which
extrapolates to a mol. wt of 200,000
Immmunoelectrophoresis of lung TAMA-]
Using the TEP conditions described
above we electrophoresed 20 jA of a
Sephadex G-200 concentrate of lung
TAMA-l as well as 20 1u of a comparable
Sephadex G-200 concentrate of normal
lung Triton membrane extract (NLTME).
After electrophoresis we added adsorbed
antiserum specific to lung TAMA-1 to the
trough and incubated the plate in a moist
chamber overnight at 4°C. The final
stained IEP plate is shown in Fig. 4 and
demonstrates the sloxv cathodic mobility
of lung TAMA-l at pH 7-6. The results
support the need to carbamylate our anti-
sera before CIEP.
Adsorption analysis by intnaunodiffusion
The DEAE- I antiserum which had been
adsorbed as described above was further
adsorbed by the DeCarvalho procedure
with a variety of extracts, in order to
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Molecular Weight (D)
FIG. 3. Mol.-wt determination for lung
TAMA-1. A 1-6 x 100cm Sephadex G-200
column was calibrated by making 3 con-
secutive runs of several mol.-wt markers
(0) and plotting the Ka, on the abscissa
and the mol. wt (log scale) on the ordinate.
Also, the averaged K (0.25) from 3 con-
secutive runs of a TTME, DEAE I eluate,
are plotted (0) and yielded an estimated
mol. wt of 200,000 for lung TAMA-1.
assess its possible origin as a normal host
protein. The immunological activity ofthe
antiserum was unaffected by these further
adsorptions (Table I). Hence there was no
TABLE I.-Adsorption analysis of the
DEAE-I lung TAMA-1: Demonstration
of anti-TAMA-l antibodies after absorb-
tion with normal serumfractions
Protein
Adsorbent (mg/ml)
Cohn fractions:
I 10*0
II, III 10 0
IV 10 0
IV-4 10*0
V 10-0
VI 10*0
Norman human lung:
Soluble extracts* 7-2
Triton extractst 5 0
Normal human organs:
Soluble extractst 8-0
Saliva (5 x concentrated) 3-3
Human embryonic lung:
(24 weeks)
Triton extracts 0-2
Soluble extracts 2-4
Human embryonic lung:
(26 weeks)
Soluble extracts 2-0
* Pool of 6 100,000g solubles.
t Pool of 5 Triton X-100 extracts concentrated
x 5 by ultrafiltration.
t Pool of 100,OOOg solubles of heart, liver, lung,
kidney and spleen.
FIG. 4.-Immunoelectrophoresis (IEP) oflung TAMA-1. We electrophoresed 20 jd ofa lung TAMA-1-
containing Sephadex G-200 fraction (1) and 20 pl of a comparable fraction of normal-lung Triton
membrane extract (3). Antiserum to lung TAMA-1 was added to the trough (2) and incubated over-
night at 4°C to give the results shown on the stained plate.
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indication by this protocol that the new
lung TAMA-1 was a normal tissue com-
ponent or that it was of embryonic origin,
at least in the available foetal tracts.
Identity analysis by immunodiffusion
Specific antisera were obtained com-
mercially and from investigators men-
tioned in Materials and Methods and were
cross-tested against DEAE-1 antiserum
and DEAE-cellulose Peak 1. Table II
TABLE II. Identity analysis ofthe DEAE-
I lung TAMA-l
Anitiserum to
(EA*
AFP*
f2 Microglobuliln*
Soluble lung TAA I,',3t
Human colostrumt
Human serum proteins+
ZN-cx2-Glycoprotein
GC-Globulin
Fibrinogen
C-reactive prot,ein
Serum Cholinesterase
IgMA
IgA
IgG
c 1-Lipoprotei
18-Lipoproteiii
Reaction with
lung
TAMA-1tt
_§
(**
()
0 () 0
()
* Antiseruim obtained firom investigators as listedl
in Materials an(l Metho(ds.
t Goat antiserum to previously (lescribed soluble
lung TAA (Veltri et al., 1977).
. Antisera obtainedl from Behring Diagnostics,
Sommerville, N.J.
§ Reaction ofnon--identity by immunodiffusion
** No reaction.
tt DEAE I fractionl.
illustrates that lung TAMA-1 is not CEA,
AFP, or our previously described soluble
lung TAA-1, 2, or 3. A precipitating anti-
serum to /2 microglobulin did not react
with lung TAMA-1. In addition, the lung
TAMA-1 did not cross-react with several
serum proteins that are elevated in cancer.
Occurrence of lung TAMA-1 in various
tissue extracts
Immunoelectrophoresis showed that
lung TAMA-1 had gamma electrophoretic
mobility (Fig. 4). Therefore the DEAE-1
antiserum was carbamylated to obtain an
49
anodal migration for IgG, in order to
detect the antigen by CIEP. Under these
conditions lung TAMA-1 migrates towards
the cathode and reacts with the carb-
amylated antiserum that now has an
anodal mobility.
Several extracts of normal lung, lung
tumours and various other tumours were
screened by CIEP to determine the dis-
tribution of the lung TAMA-1 in these
tissues. Table III shows that lung TAMA-1
was detected in 12/15 Triton extracts of
lung tumours. The antigen was not
detected in the 100,000g soluble or 3M KCI
extracts of lung tutmours or in any of the
normal lung extracts tested.
A small number of Triton extracts of
other tumours was available and these
were also tested for lung TAMA-1 (Table
III). All these extracts were negative for
the antigen.
One disturbing aspect ofthe above data
on the distribution of lung TAMA-1 was
that the antigen seemed restricted to lung-
tumour membrane Triton extracts. To
determine whether the isolation of these
antigens was unique to the Triton protocol,
the following experiment was performed.
The DEAE I fraction of a Triton X-100
extract was further treated by the 3M KCI
and sequential sonication procedures. The
samples were then tested by CIEP for
residual antigen activity.
TABLE III. Detection oflung TAMA-1 in
lung extracts by counterimmunoelectro-
phoresis (CIEP)
Tisstue, extract
Lung tumouir:
Triton X-100
100,000 g soluble
3M KCI
Breast tumour: Triton X-100
CIEP
reaction*
Protein for lung
(mg/ml) TAMA -l
0-5-0-8
2-0-4-0
0 4-0-7
10-1-4
12/15t
0/15
0/12
0/5
Colonic tumour: Triton X-l10 0-94, 1-4, 1-5 0/3
Normal lung:
Triton X-100
1(00,000 g soluble
3mI KCI
0-6-0-9
2-7, 3-6, 7-1
0-46, 0-72
0/7
0/3
0/2
* Adsorbed DEAE I antiserum was used to test
reactivity.
t Number of +Xye samples/total tested.
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TABLE IV. Effect of 3M KCl and sonica-
tion on lung TAMA-1 reactivity
CIEP
reaction*
(immuno-
P'roteill Treat- precipitin
Sample (mg/ml) ments band)
DEAE-1 oflung-
tumour Triton
pool (lung
TAIIA-1)
None
2-4 3MKCI
Sonication
+
* Adsorbed D)EAE I antiserum was use(t to test
reactivity by counterimmunoelectrophoresis.
Table IV shows that in the untreated
control samples the antigens were detected
as expected. 3M KCI treatment ofDEAE-1
however, caused a loss of lung TAMA-1
reactivity. Sonication of the extracts did
not affect the antigen.
Imrnunohistochemical localization of lung
TAMA-1 in vivo
Using the indirect immunoperoxidase
bridge method we wereable todemonstrate
a specific reaction of anti-lung TAMA-l
with formalin-embedded sections of
human squamous cell carcinoma of the
lung. Fig. 5 demonstrates a positive reac-
tion for lung TAMA-1 at a 1: 50 dilution of
the rabbit-lung TAMA-I antiserum; a
negative result was obtained when normal
rabbit serum was used. The positive
reaction was titrated and reactivity
diluted out at 1:4000. Other negative
controls included testing a 1: 50 dilution
of anti-lung TAMA-I and normal rabbit
serum against normal human bronchus.
These data, although preliminary, would
suggest that our antiserum might be of
value in a retrospective or prospective
screen of lung-cancer specimens for the
production of lung TAMA-1. We have
confirmed these findings in at least 5
additional lung-cancer patients, using
indirect immunofluorescence with the
same 1: 50 dilution of rabbit antiserum to
lung TAMA- 1.
DISCUSSION
The biochemical and immunochemical
evidence supporting the existence of lung
TAA is extensive. Several of the anti-
gens are soluble and detectable in a
variety of histological types of human
lung tumours, but most are incompletely
characterized (Schlipkoter et al., 1973;
Viza et al., 1975; Watson et al., 1974, 1975;
Yachi et al., 1968). We recently reported
on the isolation and identification of 3
soluble proteins associated with several
types of lung tumours (Veltri et al., 1977)
but these proved to be 3 normal serum
proteins produced in excess during cancer
by either the tumour or the host.
Tumour-associated membrane antigens
(TAMA) have been demonstrated by in
vivo and in vitro immunoassays. Hollins-
head et al. (1974, 1975) using a partially
purified lung TAMA isolated by sequential
low-frequency sonication, demonstrated
its reactivity by skin testing. Other in-
vestigators, using more crude lung TAMA
generated by 3M KCI solubilization, have
demonstrated cell-mediated immune
(CMI) reactivity oflung-cancer patients to
such preparations. The in vitro CMI
methods have included lymphocyte blasto-
genesis (Roth et al., 1975; Dean et al.,
1978), leucocyte-migration inhibition
(Boddie et al., 1975; Cannon et al., 1977;
McCoy et al., 1977) as well as microcyto-
toxicity (Pierce & DeVald, 1975).
We now report the isolation and identi-
fication of a membrane-bound lung anti-
gen (lung TAMA-1) extractable from
human lung squamous-cell carcinomas
with Triton X-100. An antiserum pro-
duced in rabbits against a DEAE-1
elution region of a Triton X-100 lung-
tumour membrane preparation was ex-
tensively adsorbed with normal tissue
constituents until it yielded a single
reactivity with lung-tumour Triton ex-
tracts only. This adsorbed DEAE I anti-
serum was subsequently used to monitor
purification and characterization of lung
TAMA-1.
The adsorption analysis of this anti-
serum by the method of DeCarvalho
(1973) and identity analysis by cross-
testing antisera of known specificities by
Ouchterlony double diffusion revealed
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that lung TAMA-I was not one of
numerous constitutive host proteins we
tested. Also, lung TAMA-1 could not be
identified as CEA, AFP or /2 micro-
globulin, or previously described soluble
lung TAA 1, 2 or 3 (Veltri et al., 1977).
Lung TAMA-1 demonstrated a slow
gamma-type electrophoretic mobility on
immunoelectrophoresis at pH 7-6. Partial
purification of lung TAMA-1 was ob-
tained on Sephadex G-200, where the
antigen eluted with 4500 of the protein
loaded on the column. Using a calibration
curve generated with known mol. wt
markers, lung TAMA-1 has a mol. wt of
- 200,000. By sucrose-gradient isoelectric
focusing we further purified a DEAE-I
region of a lung tumour membrane Triton
extract and demonstrated lung TAMA-1
to have an isoelectric point of - 3 0.
Due to the cathodic electrophoretic
mobility of lung TAMA-1 it became
necessary to carbamylate (Weeke, 1968)
the IgG rabbit antiserum to DEAE-J, in
order to perform a more sensitive immuno-
assay, viz. counterimmunoelectrophoresis
(CIEP). The IgG antibody altered by
carbamylation toananodal electrophoretic
mobility was used to test the presence of
lung TAMA-1 in a variety of lung and
other tumour Triton membrane extracts.
Using CIEP we confirmed the presence of
our antigen in 80% of lung tumour Triton
extracts, and it was not detected in
similar extracts of breast or colon
carcinoma.
An important observation regarding
lung TAMA-1 was its apparent denatura-
tion by treatment with 3M KCI but not by
sequential low-frequency sonication, a
protocol reported to isolate lung TAMA
(Hollinshead et al., 1974, 1975). Such data
emphasizes that different modalities of
membrane solubilization may yield differ-
ent TAA. These data serve to suggest that
lung TAMA-1 is not likely to have been
present in biologically significant amounts
in 3M KCI extracts tested by several re-
searchers (Boddie et al., 1975; Cannon et
al., 1977; Dean et al., 1978; McCoy et al.,
1977; Pierce & DeVald, 1975; Roth et al.,
1975). However, other reports by Hollins-
head et al. (1974, 1975) are more likely to
have contained lung TAMA-I. Further
characterization of our lung TAMA-1 will
clarify its relationship to other reported
lung TAMA. We attribute the isolation of
this antigen to the nondenaturing and
gentle mechanism by which Triton re-
leases proteins from membranes (Helenus
& Simons, 1975).
Finally preliminary suggestions of the
potential value of lung TAMA-1 came
from its in vivo localization by immuno-
histochemistry, with the adsorbed DEAE-
I antiserum. These data provide impetus
for future retrospective and prospective
immunologic studies on a variety of lung-
cancer specimens.
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